STOCKHOLM, March 18, 2022 /PRNewswire/ Sobi today announced that the National Medical Products Administration of China (NMPA) has approved Gamifant (emapalumab) for use in China. The indication
STOCKHOLM, Feb. 25, 2022 /PRNewswire/ Sobi today announces that the Center for Drug Evaluation (CDE) has recommended approval of Gamifant to the National Medical Products Administration of
Kineret® (anakinra) approved in Russia for the treatment of CAPS
News provided by
Share this article
Share this article
STOCKHOLM, Feb. 16, 2021 /PRNewswire/ Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the Ministry of Health of the Russian Federation has approved Kineret (anakinra) for the treatment of Cryopyrin associated periodic syndromes (CAPS). We are excited to announce the approval of this important treatment and we look forward to serving patients with CAPS in Russia, said Norbert Oppitz, Head of Immunology and International at Sobi. Today s announcement also marks a significant milestone for Sobi s future ambition, as Russia is a key market for our geographic expansion strategy over the next five years.